ERBB2 and cancer: One of these is the Cancer and Leukaemia Group B 8541 trial, which reported that patients with HER2+ disease, who received tamoxifen, had a 32 and 30% reduction in disease recurrence risk and death, respectively, compared to patients not receiving tamoxifen, a benefit not substantially less than the equivalent 39 and 36% seen in patients with HER2− disease.